Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells

The development of a prophylactic vaccine for hepatitis C virus (HCV) remains a global health challenge. Cumulative evidence supports the importance of antibodies targeting the HCV E2 envelope glycoprotein to facilitate viral clearance. However, a significant challenge for a B cell-based vaccine is...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Virol
Autors principals: Urbanowicz, Richard A., Wang, Ruixue, Schiel, John E., Keck, Zhen-yong, Kerzic, Melissa C., Lau, Patrick, Rangarajan, Sneha, Garagusi, Kyle J., Tan, Lei, Guest, Johnathan D., Ball, Jonathan K., Pierce, Brian G., Mariuzza, Roy A., Foung, Steven K. H., Fuerst, Thomas R.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2019
Matèries:
Vaccines and Antiviral Agents
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6430559/
https://ncbi.nlm.nih.gov/pubmed/30651366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.01403-18
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars